Platelet activating factor

Platelet activating factor is a lipid of Glycerophospholipids (GP) class. Platelet activating factor is associated with abnormalities such as Atherosclerosis, Acute cholecystitis without calculus, Cholecystitis, Colitis and Cholecystitis, Acute. The involved functions are known as Cell Survival, Metabolic Inhibition, lipid oxidation, Apoptosis and Oxidation. Platelet activating factor often locates in soluble, Cellular Membrane, Smooth muscle (tissue), Intima and Tissue specimen. The associated genes with Platelet activating factor are apolipoprotein A-I Milano, Homologous Gene, TSPO gene, HBEGF gene and SLC33A1 gene. The related lipids are Hydroxycholesterols, Liposomes, 25-hydroxycholesterol, Lysophosphatidylcholines and Lipopolysaccharides. The related experimental models are Knock-out, Mouse Model and Transgenic Model.

Cross Reference

Introduction

To understand associated biological information of Platelet activating factor, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with Platelet activating factor?

Platelet activating factor is suspected in Ischemia, Pleurisy, Atherosclerosis, Inflammatory disorder, Retinal Diseases, Diabetes and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with Platelet activating factor

MeSH term MeSH ID Detail
Body Weight D001835 333 associated lipids
Lung Neoplasms D008175 171 associated lipids
Adenocarcinoma D000230 166 associated lipids
Colonic Neoplasms D003110 161 associated lipids
Edema D004487 152 associated lipids
Carcinoma, Hepatocellular D006528 140 associated lipids
Hemolysis D006461 131 associated lipids
Cell Transformation, Neoplastic D002471 126 associated lipids
Inflammation D007249 119 associated lipids
Hypertension D006973 115 associated lipids
Glioma D005910 112 associated lipids
Weight Gain D015430 101 associated lipids
Hypercholesterolemia D006937 91 associated lipids
Diabetes Mellitus D003920 90 associated lipids
Brain Ischemia D002545 89 associated lipids
Seizures D012640 87 associated lipids
Diabetes Mellitus, Type 2 D003924 87 associated lipids
Arteriosclerosis D001161 86 associated lipids
Atherosclerosis D050197 85 associated lipids
Pancreatic Neoplasms D010190 77 associated lipids
Per page 10 20 50 100 | Total 288

PubChem Associated disorders and diseases

What pathways are associated with Platelet activating factor

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with Platelet activating factor?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with Platelet activating factor?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with Platelet activating factor?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with Platelet activating factor?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with Platelet activating factor?

Knock-out

Knock-out are used in the study 'A cardioprotective role for platelet-activating factor through NOS-dependent S-nitrosylation.' (Leary PJ et al., 2008).

Mouse Model

Mouse Model are used in the study 'A regulatory role of LPCAT1 in the synthesis of inflammatory lipids, PAF and LPC, in the retina of diabetic mice.' (Cheng L et al., 2009).

Transgenic Model

Transgenic Model are used in the study 'Heterogeneity in the sn-1 carbon chain of platelet-activating factor glycerophospholipids determines pro- or anti-apoptotic signaling in primary neurons.' (Ryan SD et al., 2008).

Related references are published most in these journals:

Model Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

NCBI Entrez Crosslinks

All references with Platelet activating factor

Download all related citations
Per page 10 20 50 100 | Total 8526
Authors Title Published Journal PubMed Link
Satouchi K et al. Application of selected ion monitoring to determination of platelet-activating factor. 1983 J. Biochem. pmid:6423622
Hillmar I and Zöllner N Saturated and unsaturated 1-0-alkyl-2-0-acetoyl-sn-glycero-3-phosphocholines and 2-lyso derivatives from ratfish liver oil. Effect on adenosine 3':5'-cyclic monophosphate concentration in hepatocyte suspensions. 1983 Res Exp Med (Berl) pmid:6310713
Mauco G et al. Platelet activating factor (PAF-acether) promotes an early degradation of phosphatidylinositol-4,5-biphosphate in rabbit platelets. 1983 FEBS Lett. pmid:6311620
Camussi G et al. Release of platelet activating factor in rabbits with antibody-mediated injury of the lung: the role of leukocytes and of pulmonary endothelial cells. 1983 J. Immunol. pmid:6311899
Hwang SB et al. Specific receptor sites for 1-O-alkyl-2-O-acetyl-sn-glycero-3-phosphocholine (platelet activating factor) on rabbit platelet and guinea pig smooth muscle membranes. 1983 Biochemistry pmid:6313047
Shukla SD and Hanahan DJ An early transient decrease in phosphatidylinositol 4,5-bisphosphate upon stimulation of rabbit platelets with acetylglycerylether phosphorylcholine (platelet activating factor). 1983 Arch. Biochem. Biophys. pmid:6320731
MacIntyre DE and Pollock WK Platelet-activating factor stimulates phosphatidylinositol turnover in human platelets. 1983 Biochem. J. pmid:6411067
Larsen GL and Henson PM Mediators of inflammation. 1983 Annu. Rev. Immunol. pmid:6399978
Albert DH and Snyder F Biosynthesis of 1-alkyl-2-acetyl-sn-glycero-3-phosphocholine (platelet-activating factor) from 1-alkyl-2-acyl-sn-glycero-3-phosphocholine by rat alveolar macrophages. Phospholipase A2 and acetyltransferase activities during phagocytosis and ionophore stimulation. 1983 J. Biol. Chem. pmid:6401298
McManus LM et al. Thromboxane B2 (TxB2) release following acetyl glyceryl ether phosphorylcholine (AGEPC) infusion in the rabbit. 1983 Immunopharmacology pmid:6832960
König W et al. On the biological role of lipid chemotactic factors. 1983 Agents Actions Suppl. pmid:6404145
Ninio E et al. Biosynthesis of platelet-activating factor (PAF-acether). V. Enhancement of acetyltransferase activity in murine peritoneal cells by calcium ionophore A23187. 1983 Biochim. Biophys. Acta pmid:6405792
Alam I et al. Human and rabbit platelets form platelet-activating factor in response to calcium ionophore. 1983 Thromb. Res. pmid:6407140
Ostermann G et al. Studies on the stimulation of human blood platelets by semi-synthetic platelet-activating factor. 1983 Thromb. Res. pmid:6408754
O'Flaherty JT et al. 5-L-hydroxy-6,8,11,14-eicosatetraenoate potentiates the human neutrophil degranulating action of platelet-activating factor. 1983 Biochem. Biophys. Res. Commun. pmid:6403011
Drapier JC et al. Lipid-mediator synthesis in peritoneal macrophages from mice injected with immunostimulants. 1983 Biochim. Biophys. Acta pmid:6131693
Otsuka A et al. alpha-Adrenergic blocking action of 1-O-hexadecyl-2-O-acetyl-sn-glycero-3-phosphocholine in rats. 1983 Clin Exp Hypertens A pmid:6133661
Jouvin-Marche E et al. Effect of the Ca2+ antagonist nifedipine on the release of platelet-activating factor (PAF-acether), slow-reacting substance and beta-glucuronidase from human neutrophils. 1983 Eur. J. Pharmacol. pmid:6134631
Haddad ZH and Green A State--and dynamics--of the art: a current review. IgE-mediated immediate hypersensitivity reactions: cellular events and pharmacologic mediators. 1983 J Asthma pmid:6190793
Sano K et al. A role of calcium-activated phospholipid-dependent protein kinase in human platelet activation. Comparison of thrombin and collagen actions. 1983 J. Biol. Chem. pmid:6218169
Vargaftig BB et al. Synergized activation of human platelets by epinephrine and platelet-activating factor-acether is adenosine diphosphate and thromboxane A2-independent. 1983 Adv. Prostaglandin Thromboxane Leukot. Res. pmid:6221558
Voelkel NF et al. Platelet-activating factor causes pulmonary vasoconstriction and edema via platelet-independent leukotriene formation. 1983 Adv. Prostaglandin Thromboxane Leukot. Res. pmid:6221590
Kloprogge E et al. Properties of PAF-acether-induced platelet aggregation and secretion. Studies in gel-filtered human platelets. 1983 Thromb. Res. pmid:6222507
Swendsen CL et al. 1-O-alkyl-2-acyl-sn-glycero-3-phosphocholine: a novel source of arachidonic acid in neutrophils stimulated by the calcium ionophore A23187. 1983 Biochem. Biophys. Res. Commun. pmid:6407484
Bessin P et al. Acute circulatory collapse caused by platelet-activating factor (PAF-acether) in dogs. 1983 Eur. J. Pharmacol. pmid:6687572
Mueller HW et al. 1-O-alkyl-linked phosphoglycerides of human platelets: distribution of arachidonate and other acyl residues in the ether-linked and diacyl species. 1983 Lipids pmid:6419001
Hallam TJ et al. The role of 1-O-alkyl-2-acetyl-sn-glyceryl-3-phosphorylcholine (AcGEPC) and palmitoyl-lysophosphatidate in the responses of human blood platelets to collagen and thrombin. 1983 FEBS Lett. pmid:6617886
Roussi J et al. [Success of treatment with a low-molecular-weight heparin fraction in a case of pulmonary embolism complicated by heparin-induced thrombopenia]. 1983 Nouv Rev Fr Hematol pmid:6622253
Valone FH and Goetzl EJ Enhancement of human polymorphonuclear leukocyte adherence by the phospholipid mediator 1-O-hexadecyl-2-acetyl-sn-glycero-3-phosphorylcholine (AGEPC). 1983 Am. J. Pathol. pmid:6624880
Barradas MA et al. The effect of fenfluramine on collagen-induced platelet aggregation in vitro. 1983 Br J Clin Pharmacol pmid:6626443
Korth R et al. 1-O-alkyl-2-O-acetyl-sn-glycero-3-phosphocholines: influence on aggregation and [3H]serotonin release of human thrombocytes. 1983 Chem. Phys. Lipids pmid:6627525
Moschidis MC et al. Phosphono-platelet activating factor I. Synthesis of 1-O-hexadecyl-2-O-acetyl-glyceryl-3-(2-trimethyl ammonium-methyl) phosphonate and its platelet activating potency. 1983 Chem. Phys. Lipids pmid:6627527
Heffner JE et al. Acetyl glyceryl ether phosphorylcholine-stimulated human platelets cause pulmonary hypertension and edema in isolated rabbit lungs. Role of thromboxane A2. 1983 J. Clin. Invest. pmid:6822668
Vargaftig BB et al. Convulxin-induced activation of intact and of thrombin-degranulated rabbit platelets: specific crossed desensitisation with collagen. 1983 Eur. J. Pharmacol. pmid:6628537
Farr RS et al. Human serum acid-labile factor is an acylhydrolase that inactivates platelet-activating factor. 1983 Fed. Proc. pmid:6628702
Denjean A et al. Acute effects of intratracheal administration of platelet-activating factor in baboons. 1983 J Appl Physiol Respir Environ Exerc Physiol pmid:6629917
Benveniste J et al. The actions of Paf-acether (platelet-activating factor) on guinea-pig isolated heart preparations. 1983 Br. J. Pharmacol. pmid:6652376
Garcia Gil M and Sanchez Crespo M Dansylcadaverine and rimantadine inhibition of phagocytosis, PAF-acether release, and phosphatidylcholine synthesis in human polymorphonuclear leukocytes. 1983 Immunopharmacology pmid:6654649
Tokumura A et al. Biphasic action of platelet-activating factor on isolated guinea-pig ileum. 1983 Lipids pmid:6656539
Hamasaki Y et al. [Effects of platelet activating factor (PAF:AGEPC) on airway and pulmonary vascular constriction of guinea pigs--with special reference to the relation with TXA2]. 1983 Kokyu To Junkan pmid:6658209
Björk J et al. Paf-acether (platelet-activating factor) increases microvascular permeability and affects endothelium-granulocyte interaction in microvascular beds. 1983 Acta Physiol. Scand. pmid:6659994
Björk J and Smedegård G Acute microvascular effects of PAF-acether, as studied by intravital microscopy. 1983 Eur. J. Pharmacol. pmid:6662199
Holt PG et al. Platelet serotonin release by human polymorphonuclear leucocytes stimulated by cotton dust bacteria. 1983 Clin. Exp. Immunol. pmid:6831770
Yamashita M et al. The metabolism of platelet activating factor in platelets and plasma of various animals. 1983 J Toxicol Sci pmid:6663653
McDonald TP and Kalmaz GD Effects of thrombopoietin on the number and diameter of marrow megakaryocytes of mice. 1983 Exp. Hematol. pmid:6832243
Masugi F et al. [Kidney medulla and hypertension, with special reference to antihypertensive lipids]. 1983 Nihon Jinzo Gakkai Shi pmid:6663856
Lewis JC et al. Platelet-activating factor effects on pulmonary ultrastructure in rabbits. 1983 Exp. Mol. Pathol. pmid:6832335
Tanaka S et al. Studies on the hypotensive effects of platelet activating factor (PAF, 1-O-alkyl-2-acetyl-sn-glyceryl-3-phosphorylcholine) in rats, guinea pigs, rabbits, and dogs. 1983 J. Pharmacobio-dyn. pmid:6668545
Levy JV Calmodulin antagonists inhibit aggregation of human, guniea pig and rabbit platelets induced with platelet activating factor. 1983 FEBS Lett. pmid:6832368
Saeki S et al. Hypotensive activity of 1-O-hexadecyl-2-O-acetyl-sn-glycero-3-phosphocholine in rats with various types of hypertension. 1983 Med J Osaka Univ pmid:6669136
Mueller HW et al. Biosynthesis of platelet activating factor in rabbit polymorphonuclear neutrophils. 1983 J. Biol. Chem. pmid:6406476
Lee TC et al. Stimulation of calcium uptake by 1-alkyl-2-acetyl-sn-glycero-3-phosphocholine (platelet-activating factor) in rabbit platelets: possible involvement of the lipoxygenase pathway. 1983 Arch. Biochem. Biophys. pmid:6407399
Touqui L et al. Conversion of 3H-PAF acether by rabbit platelets is independent from aggregation: evidences for a novel metabolite. 1983 Biochem. Biophys. Res. Commun. pmid:6838557
Billah MM and Johnston JM Identification of phospholipid platelet-activating factor (1-0-alkyl-2-acetyl-sn-glycero-3-phosphocholine) in human amniotic fluid and urine. 1983 Biochem. Biophys. Res. Commun. pmid:6407483
Worthen GS et al. Platelet-activating factor causes neutrophil accumulation and edema in rabbit lungs. 1983 Chest pmid:6839840
Heffner JE et al. Platelet-induced pulmonary hypertension and edema. A mechanism involving acetyl glyceryl ether phosphorylcholine and thromboxane A2. 1983 Chest pmid:6839854
Vargaftig BB Phospholipids, particularly platelet-activating factor (PAF-acether), in experimental bronchoconstriction. 1983 Agents Actions Suppl. pmid:6575594
Page CP et al. PAF-acether: a putative mediator of asthma and inflammation. 1983 Agents Actions Suppl. pmid:6575595
Hartung HP et al. Platelet activating factor (PAF) induces the oxidative burst in macrophages. 1983 Int. J. Immunopharmacol. pmid:6874164
1st International Symposium on Platelet-Activating Factor (PAF-ACETHER, AGEPC) and structurally related ether-lipids. Paris (France) June 26-29, 1983. Abstracts. 1983 J Pharmacol pmid:6876807
Camussi G et al. Acute lung inflammation induced in the rabbit by local instillation of 1-0-octadecyl-2-acetyl-sn-glyceryl-3-phosphorylcholine or of native platelet-activating factor. 1983 Am. J. Pathol. pmid:6859232
Cargill DI et al. Aggregation, release and desensitization induced in platelets from five species by platelet activating factor (PAF). 1983 Thromb. Haemost. pmid:6879508
Sánchez-Crespo M et al. Presence in normal human urine of a hypotensive and platelet-activating phospholipid. 1983 Am. J. Physiol. pmid:6859262
Lumb RH et al. Spontaneous and protein-catalyzed transfer of 1-alkyl-2-acetyl-sn-glycero-3-phosphocholine (platelet-activating factor) between phospholipid bilayers. 1983 Biochim. Biophys. Acta pmid:6860678
Suquet CM and Leid RW Aggregation of equine platelets by PAF (platelet-activating factor). 1983 Inflammation pmid:6862593
Blank ML and Snyder F Improved high-performance liquid chromatographic method for isolation of platelet-activating factor from other phospholipids. 1983 J. Chromatogr. pmid:6863454
Simrock R et al. [Reversible inhibition of thrombocyte stimulation by acetylsalicylic acid and its role in antithrombotic therapy]. 1983 Klin. Wochenschr. pmid:6865264
Hadváry P and Baumgartner HR Activation of human and rabbit blood platelets by synthetic structural analogs of platelet activating factor. 1983 Thromb. Res. pmid:6868019
O'Flaherty JT and Wykle RL Biology and biochemistry of platelet-activating factor. 1983 Clin Rev Allergy pmid:6370406
Tiffany ML Technical considerations for platelet aggregation and related problems. 1983 Crit Rev Clin Lab Sci pmid:6370596
Vermylen J et al. Normal mechanisms of platelet function. 1983 Clin Haematol pmid:6301715
Pieroni G and Hanahan DJ Metabolic behavior of acetyl glyceryl ether phosphorylcholine on interaction with rabbit platelets. 1983 Arch. Biochem. Biophys. pmid:6870274
Billah MM and Lapetina EG Platelet-activating factor stimulates metabolism of phosphoinositides in horse platelets: possible relationship to Ca2+ mobilization during stimulation. 1983 Proc. Natl. Acad. Sci. U.S.A. pmid:6341992
Lapetina EG and Siegel FL Shape change induced in human platelets by platelet-activating factor. Correlation with the formation of phosphatidic acid and phosphorylation of a 40,000-dalton protein. 1983 J. Biol. Chem. pmid:6345519
Camussi G et al. Inhibitory effect of prostacyclin (PGI2) on neutropenia induced by intravenous injection of platelet-activating-factor (PAF) in the rabbit. 1983 Prostaglandins pmid:6346397
Iñarrea P et al. Platelet-activating factor: an effector substance of the vasopermeability changes induced by the infusion of immune aggregates in the mouse. 1983 Immunopharmacology pmid:6347969
Satouchi K [Platelet activating factor (PAF)--a new chemical mediator of inflammation]. 1983 Seikagaku pmid:6350499
McGowan EB and Detwiler TC Characterization of the thrombin-induced desensitization of platelet activation by thrombin. 1983 Thromb. Res. pmid:6356458
Weksler BB Platelets and the inflammatory response. 1983 Clin. Lab. Med. pmid:6360503
Machin SJ et al. Defective platelet aggregation to the calcium ionophore A23187 in a patient with a lifelong bleeding disorder. 1983 J. Clin. Pathol. pmid:6413552
Alam I et al. Metabolism of platelet-activating factor by blood platelets and plasma. 1983 Lipids pmid:6413803
Pinckard RN Platelet-activating factor. 1983 Hosp. Pract. (Off. Ed.) pmid:6414941
Camussi G et al. The release of platelet-activating factor from human endothelial cells in culture. 1983 J. Immunol. pmid:6415166
Bonnet J et al. Dependency of the Paf-acether induced bronchospasm on the lipoxygenase pathway in the guinea-pig. 1983 Prostaglandins pmid:6419289
Pazzi A et al. [Platelet activation in vivo. Electron microscopy study of a case of type II diabetes]. 1983 Mar-Apr G Clin Med pmid:6884636
Mojarad M et al. Platelet-activating factor increases pulmonary microvascular permeability and induces pulmonary edema. A preliminary report. 1983 May-Jun Bull Eur Physiopathol Respir pmid:6882949
Sänze JU et al. On the nature of the vasoreactivity depressing factor (VDF) in inflammation and anaphylaxis in the rat and mouse. 1984 Biomed. Biochim. Acta pmid:6440544
Sills RH Thrombotic thrombocytopenic purpura. I. Pathophysiology and clinical manifestations. 1984 Am J Pediatr Hematol Oncol pmid:6442830
Lartigue-Mattei C et al. Pharmacokinetic study of 3H-labelled PAF-acether II. Comparison with 3H-labelled lyso-PAF-acether after intravenous administration in the rabbit and protein binding. 1984 Agents Actions pmid:6532184
Kulikov VI et al. [Incorporation of 1-0-alkyl-2-acetyl-sn-glycerol-3-phosphocholine into human plasma lipoproteins in vitro. Effect of the lecithin:cholesterol acyltransferase activity of plasma]. 1984 Biokhimiia pmid:6542803
Buxton DB et al. Stimulation of hepatic glycogenolysis by acetylglyceryl ether phosphorylcholine. 1984 J. Biol. Chem. pmid:6693418
Oxholm P et al. Lack of evidence for human lymphokines with thrombocyte aggregating activity. An in vitro study. 1984 Allergy pmid:6528957
Hwang SB et al. Effects of nonsteroid antiinflammatory drugs on the specific binding of platelet activating factor to membrane preparations of rabbit platelets. 1984 Thromb. Res. pmid:6429890
Colditz IG and Movat HZ Kinetics of neutrophil accumulation in acute inflammatory lesions induced by chemotaxins and chemotaxinigens. 1984 J. Immunol. pmid:6470487
Patterson R et al. Airway responses to sequential challenges with platelet-activating factor and leukotriene D4 in rhesus monkeys. 1984 J. Lab. Clin. Med. pmid:6470563
Kumar R et al. A facile route to semi-synthesis of acetyl glycerylether phosphoethanolamine and its choline analogue. 1984 J. Lipid Res. pmid:6707528
Bult H et al. Complement derived factors and prostacyclin formation by rabbit isolated peritoneum and cultured mesothelial cells. 1984 Agents Actions Suppl. pmid:6382974
Hechtman HB et al. Role of humoral mediators in adult respiratory distress syndrome. 1984 Chest pmid:6383742
Kelton JG et al. The detection of a platelet-agglutinating factor in thrombotic thrombocytopenic purpura. 1984 Ann. Intern. Med. pmid:6333196
Bussolino F et al. Release of platelet-activating factor (PAF)-like material from human lymphoid cell lines. 1984 Exp. Hematol. pmid:6333353